BioXcel Therapeutics, Inc. (BTAI)

In March 2026, BioXcel Therapeutics closed an $8.0 million registered direct offering and reported positive Phase 2 results for BXCL501 in opioid withdrawal, as well as its Fourth Quarter and Full-Year 2025 financial results. In January 2026, a law firm encouraged shareholders to contact them, signaling potential legal or financial concerns. The stock has experienced significant volatility and a substantial decrease in price over the past year and five years due to clinical setbacks, including FDA rejections for BXCL501.

Information regarding the specific demand seasonality for BioXcel Therapeutics, Inc. products and services is not readily available. A definitive statement on demand seasonality cannot be made based on the current information.

BioXcel Therapeutics, Inc. (BTAI) is a clinical-stage biopharmaceutical company using AI to develop new medicines in neuroscience and immuno-oncology. Their commercial product is IGALMI®, a sublingual film of dexmedetomidine, approved by the FDA for acute agitation associated with schizophrenia or bipolar disorder in adults. The company's pipeline includes BXCL501 for agitation and substance use disorders, BXCL701 for aggressive cancers, BXCL502 for stress-related neuropsychiatric symptoms, BXCL503 targeting apathy in dementia, and BXCL504 for apathy and aggression in dementia.

BioXcel Therapeutics, Inc. is headquartered in New Haven, Connecticut, and primarily operates in the United States.

BioXcel Therapeutics' brand reputation has been significantly affected by its inability to generate meaningful revenue, substantial net losses, and clinical setbacks, including FDA rejections for BXCL501. This has led to shareholder dilution, a sharp decline in stock price, and potential concerns regarding the company's standing, as indicated by a law firm encouraging shareholders to discuss their rights.

BioXcel Therapeutics, Inc. has a mix of institutional, insider, and retail ownership. Major institutional owners include Millennium Management Llc, Vanguard Group Inc, and Oaktree Capital Management Lp. As of December 2025, 40 institutions reported a stake in BTAI, holding a total of 3,537,053 shares. Vimal Mehta is the largest individual shareholder, owning 17.60 million shares, representing 64.99% of the company.